NCT07670884RecruitingPhase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects
Fujian Shengdi Pharmaceutical Co., Ltd.2 sites in 1 country675 target enrollmentStarted: July 24, 2026Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Recruiting
- Enrollment
- 675
- Locations
- 2
- Primary Endpoint
- Percentage change from baseline in body weight after 52 weeks of treatment
Study Overview
Brief Summary
This study aims to evaluate the efficacy and safety of HRS9531 tablets compared with placebo in reducing body weight in overweight or obese subjects after 52 weeks of treatment.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male or female subjects, 18-75 years of age at the time of signing informed consent;
- •At screening visit, BMI ≥ 28 kg/m2 or ≥ 24 kg/m2 with at least one weight-related comorbidity;
- •Diet and exercise control for at least 3 months before screening visit, and the weight change does not exceed 5% within the last 3 months;
- •Able and willing to provide a written informed consent.
Exclusion Criteria
- •Presence of clinically significant lab or ECG results that may affect the evaluation of the efficacy or safety of the study drug at screening visit;
- •Uncontrollable severe hypertension;
- •PHQ-9 score ≥ 15;
- •Medical history or illness that affects body weight;
- •History of diabetes;
- •Acute or chronic hepatitis;
- •History of severe cardiovascular and cerebrovascular diseases within 6 months prior to screening;
- •Any organ-system malignancies developed within 5 years;
- •Acute infection, acute trauma, or medium to large surgery within 30 days prior to screening;
- •Confirmed or suspected depression, bipolar disorder, suicidal tendencies, schizophrenia, or other serious mental illness, mentally incapacitated or speech-impaired;
- •Use of any medication or treatment that may have caused significant weight change within 90 days;
- •History of bariatric surgery;
- •Known or suspected hypersensitivity to trial product(s) or related products;
- •History of alcohol and/or substance abuse or drug abuse;
- •History of blood donation or blood loss in the 3 months before screening, or blood transfusion in the 2 months before screening;
- •Surgery is planned during the trial;
- •The investigators determined that other conditions were inappropriate for participation in this clinical trial.
Arms & Interventions
HRS9531 Tablet Group
Experimental
HRS9531 tablet.
Intervention: HRS9531 Tablet (Drug)
HRS9531 Tablet Placebo Group
Placebo Comparator
HRS9531 tablet placebo.
Intervention: HRS9531 Tablet Placebo (Drug)
Outcomes
Primary Outcomes
Percentage change from baseline in body weight after 52 weeks of treatment
Time Frame: After 52 weeks of treatment.
Proportion of subjects with weight loss of ≥ 5% from baseline in body weight after 52 weeks of treatment
Time Frame: After 52 weeks of treatment.
Secondary Outcomes
- Proportion of subjects with weight loss of ≥ 10% from baseline in body weight after 52 weeks of treatment(After 52 weeks of treatment.)
- Proportion of subjects with weight loss of ≥ 15% from baseline in body weight after 52 weeks of treatment(After 52 weeks of treatment.)
- Proportion of subjects with weight loss of ≥ 20% from baseline in body weight after 52 weeks of treatment(After 52 weeks of treatment.)
- Change from baseline in waist circumference after 52 weeks of treatment(After 52 weeks of treatment.)
- Change from baseline in body weight after 52 weeks of treatment(After 52 weeks of treatment.)
- Change from baseline in BMI (Body Mass Index) after 52 weeks of treatment(After 52 weeks of treatment.)
- Change from baseline in blood pressure after 52 weeks of treatment(After 52 weeks of treatment.)
- Change from baseline in fasting plasma glucose after 52 weeks of treatment(After 52 weeks of treatment.)
- Change from baseline in fasting serum insulin after 52 weeks of treatment(After 52 weeks of treatment.)
- Change from baseline in glycosylated hemoglobin after 52 weeks of treatment(After 52 weeks of treatment.)
- Change from baseline in blood lipid after 52 weeks of treatment(After 52 weeks of treatment.)
- Change from baseline in blood uric acid after 52 weeks of treatment(After 52 weeks of treatment.)
- Number of treatment serious adverse events (SAEs) within 57 weeks(Within 57 weeks.)
- Number of treatment adverse events (AEs) within 57 weeks(Within 57 weeks.)
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Recruiting
Phase 2
A Research Study to Investigate the Efficacy and Safety of HRS9531 Tablets in Participants With Type 2 Diabetes MellitusT2DMNCT07599410Fujian Shengdi Pharmaceutical Co., Ltd.240
Recruiting
Phase 3
A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney DiseaseChronic Kidney DiseaseNCT07419828Shandong Suncadia Medicine Co., Ltd.5,386
Recruiting
Phase 3
Phase III Study of HRS-7535 for Hypertension With Overweight or ObesityHypertension With Overweight or ObesityNCT07528027Shandong Suncadia Medicine Co., Ltd.648
Recruiting
Phase 2
A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated SteatohepatitisMetabolic Dysfunction-Associated Steatohepatitis (MASH)NCT07660848Fujian Shengdi Pharmaceutical Co., Ltd.160
Active, not recruiting
Phase 2
Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate HypertensionMild to Moderate HypertensionNCT07297797Fujian Shengdi Pharmaceutical Co., Ltd.238